|
Market Cap (24-May) $66,720,148 (584th) |
Close (30-Jun) $0.040 |
Volume (30-Jun) 696,012 |
Shortsold (16-Jan) 98 (0.00%) (641st) |
|
52w High $0.099 |
52w Low $0.021 |
P/E 25.97 |
EPS 0 |
ACW released this announcement to the ASX on 27 April 2022, 8:50. The announcement is marked as price sensitive, and is 22 page(s) in length and 2.07MB in size.
You can view all announcements from ACW and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACW was 0.008% short sold according to ASIC data. It was ranked the 645th most shorted stock on the ASX. It is now ranked as the 641st most shorted stock on the ASX with 0.000% of total shares short sold as of the latest reported data (16 January 2025).
| Other Recent Announcements from ACW | |
|---|---|
| ACW CEO presentation on emerging oral Alzheimers therapies | 21 June 2023, 8:50 |
| ACW CEO & CMO present at BIO International Convention | 5 June 2023, 9:06 |
| ACW AD trial amendment and Clinical Science Forum slides | 24 May 2023, 8:20 |
| ACW positive XanaMIA results webcast slide presentation | 27 April 2022, 8:50 |
| ACW announces positive XanaMIA results for Xanamem | 27 April 2022, 8:49 |
| Trading Halt | 22 April 2022, 9:09 |
| Appendix 3Y - Dr Steven Gourlay | 6 April 2022, 11:42 |
You must be logged in to post a reply.
Actinogen Medical 